Early Life
Marc Rubiralta's journey began with the foundation of Werfen, a company his father, Josep María Rubiralta, co-founded in 1966. Rubiralta's family has been fully committed to Werfen's growth and future.
Rise to Success
Marc Rubiralta's career advanced, and he became the Chairman of Werfen in January 2019. During his tenure, Werfen has expanded its global presence. One of the most notable deals was the acquisition of Immucor, a company with a global presence in transfusion and transplant in vitro diagnostics. Werfen's revenue in 2024 was 2.184 billion euros (approximately $2.37 Billion USD), and the company made a net profit of 170 million euros (approximately $185 Million USD).
Key Business Strategies
Key strategies include commercial expansion, especially in the United States and China, and the fostering of significant professionalization within the company. Werfen focuses on specialized diagnostics solutions for hospitals and clinical laboratories. The company has expanded through acquisitions, including Tem and Accriva Diagnostics. Werfen's vision is to be the first choice of the most advanced laboratory and point-of-care customers worldwide.
Philanthropy
Information on Marc Rubiralta's specific philanthropy amounts could not be found in the search results. However, the company's values include giving back to society.